Clinical trial
A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
NCT00508157 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- November 30, 2007
- Completion date
- March 31, 2009
- Enrollment
- 125 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.